Orbimed Advisors Llc bought $34.9M of Braveheart Bio (BRVE)
Executed Aug 7, disclosed Aug 11, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 11), the stock returned +5.0% (delay-adjusted); from the execution session (Aug 7), -10.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Orbimed Advisors Llc (Director) filed 15 Form 4 reports as a reporting entity in the trailing twelve months (7 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Sionna Therapeutics, Inc. (SION). Across 7 priced purchase filings, the average 21-session return was +16.9% from execution and +18.9% from disclosure (delay-adjusted; derived). The largest single filing was $38.9M of ELVN (858,646 sh across 3 lots, as filed), executed Jun 22.
Healthcare · Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→